The Clinical and Economic Burden of Nonalcoholic Steatohepatitis-Reference-Cited by-同舟云学术

The Clinical and Economic Burden of Nonalcoholic Steatohepatitis

Published:2018-09-19 Issue:4 Volume:17 Page:345-349
ISSN:2195-9595
Container-title:Current Hepatology Reports
language:en
Short-container-title:Curr Hepatology Rep

Author:

Lam Brian,Kurzke Kyle,Younossi Zobair

Publisher

Springer Science and Business Media LLC

Subject

Virology,Hepatology

Link

http://link.springer.com/article/10.1007/s11901-018-0423-9/fulltext.html

Reference37 articles.

1. •• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84 This is the first meta-analysis which provides region by region detail regarding the prevalence of NAFLD and related metabolic comorbidities along with long-term clinical outcomes.

2. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.

3. Fan J-G, Zhu J, Li X-J, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43(3):508–14.

4. Zhou Y-J, Li Y-Y, Nie Y-Q, Ma J-X, Lu L-G, Shi S-L, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007;13(47):6419–24.

5. Li H, Wang Y-J, Tan K, Zeng L, Liu L, Liu F-J, et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. HBPD INT. 2009;8(4):377–82.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics;Clinics and Research in Hepatology and Gastroenterology;2024-08

2. Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT;BMC Gastroenterology;2020-10-31

3. Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease;Current Hepatology Reports;2020-09-09

4. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD);Scandinavian Journal of Gastroenterology;2020-06-01